Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Quattroflow™ Introduces 5050 Series Quaternary Diaphragm Pumps

Published: Tuesday, May 14, 2013
Last Updated: Tuesday, May 14, 2013
Bookmark and Share
Ideal for use in demanding biotech and pharmaceutical applications.

Quattroflow™ has announced the introduction of its 5050 Series Quaternary Diaphragm Pump to its family of biotech and pharmaceutical pumps.

This innovative pump system features compact dimensions, multi-directional connections and the ability to satisfy a wide variety of flow-rate requirements, which makes it ideal for use in demanding biotech and pharmaceutical applications.

The 5050 pump provides multi-option installation flexibility and a compact design. The unit is drainable and cleanable, and includes multi-directional pump-head connections and positioning.

The 5050 pump features a 225mm (8.86”) chamber diameter and 50mm (1-1/2”) flange porting.

The 5050 pump has a wide flow range from 50 to 5,000 L/hr (13 to 1,321 gph), with maximum pressure to 6 bar at 20°C (87 psi at 68°F). The complete flow range can be achieved with one drive, no further drive options needed.

The pump chamber is available in 316L stainless steel for multiple-use and polypropylene (PP) for single-use applications. The pump’s valves are constructed of EPDM, while the diaphragm is Santoprene® (EPDM/PP compound).

Quattroflow’s positive displacement pumps incorporate a four piston-diaphragm technology with no mechanical seals that is driven by an eccentric shaft and motor.

Quattroflow products primarily serve the biotech and pharmaceutical industries that require gentle displacement, reliability, product safety, purity and cleanability.

The 5050 pump can be found in multiple or single-use applications within cross-flow systems, chromatography devices and centrifuges.

Quattroflow is a leading brand from Almatec, which is part of Dover Corporation’s Pump Solutions Group (PSG®).


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Designing Better Drugs
A rational drug engineering approach could breathe new life into drug development.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
New Model to Enhance Zika Virus Research
The model will allow researchers to better understand how the virus causes disease and aid in the development of antiviral compounds and vaccines.
Improving Flu Vaccine Effectiveness
NIH study finds factors that may influence influenza vaccine effectiveness.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
CNS Inflammation: A Pathway and Possible Drug Target
Scientists have long known that the central nervous system (CNS) has a remarkable ability to limit excessive inflammation in the presence of antigens or injury, but how it works has been unclear.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!